P-321 Real-world Outcomes in Myeloma Patients with T(11;14): a Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database

onset of neutropenia, anemia, and thrombocytopenia was < 1 mo (both Cohorts); median time to resolution was ≤0.26 mo (Cohort B) and ≤0.46 mo (Cohort D).TEAEs led to IBER dose interruptions in 47 (52.2%) and 56 (52.3%) pts in Cohorts B and D, and dose reductions in 22 (24.4%) and 20 (18.7%) pts in Cohorts B and D, respectively.Epoetin was used in 15 (16.7%) and 13 (12.1%)pts in Cohorts B and D, and G-CSF was used for neutropenia in 33/44 (75.0%) and 40/66 (60.6%) pts in Cohorts B and D, respectively.TEAEs led to IBER discontinuation in 6 (6.7%) and 5 (4.7%) pts in Cohorts B and D; of these, 3 (3.3%)and 1 (0.9%) pt(s) discontinued due to hematologic TEAEs, respectively.ER analysis showed that a higher IBER PK exposure was associated with a higher probability and earlier occurrence of Gr ≥3 neutropenia (P<0.05) and Gr ≥3 thrombocytopenia (P<0.05).Conclusions: The all-oral regimen of IBER+DEX showed a tolerable safety profile in pts with RRMM.TEAEs were manageable with dose modifications, dose interruptions, and G-CSF, and few pts discontinued IBER due to TEAEs.